相关实验视频

Updated: Sep 19, 2025

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

重症肥胖患者的甘油三-葡萄糖指数和28天全因死亡率:MIMIC-IV数据库分析

Wen-Qiang Wang¹, Mei-Zhu Chen¹, Yan-Hui Yang¹

¹Fuzhou First General Hospital Affiliated with Fujian Medical University, Fuzhou, Fujian, China.

Journal of clinical lipidology

|June 17, 2025

概括

甘油三糖 (TyG) 指数与重症肥胖患者28天死亡率较高有关. 较高的TyG指数水平独立预测了短期死亡风险的增加.

科学领域:

关键护理医学关键护理医学
代谢障碍代谢障碍代谢障碍
生物标志物生物标志物

背景情况:

甘油三糖指数 (TyG) 是一种已知的胰岛素耐药性的标志物.
胰岛素抵抗与各种代谢障碍有关.
肥胖的重症患者代表了一个易受伤害的人群,具有复杂的代谢挑战.

研究的目的:

调查TyG指数与28天全因死亡率之间的关联.
确定TyG指数是否是肥胖重症患者死亡率的独立预测指标.
探索TyG指数和死亡率之间的剂量反应关系.

主要方法:

利用MIMIC-IV数据库对肥胖成人危急病患者 (BMI ≥30 kg/m2) 的数据.
计算的TyG指数为ln[禁食甘油三 (mg/dL) ×禁食葡萄糖 (mg/dL) /2].
采用Cox比例危险模型和限制立方线 (RCS) 进行分析,包括子组分析.

主要成果:

较高的TyG指数四分位数与28天死亡率的增加显著相关 (日志排名P < .001).
泰格指数每增加1个单位,与死亡风险上升41%相关 (HR = 1.41).
在最高四分位数 (Q4) 的患者比最低四分位数 (Q1) 有98%的更高风险 (HR = 1.98),而RCS在TyG指数>9.25以上的风险增加.

结论:

泰格指数与肥胖重症患者28天全因死亡率显著相关.
提升的TyG指数水平是这个人群中短期死亡率的独立预测指标.
这些发现突显了TyG指数在风险分层中的潜在临床实用性.

关键词:

所有原因的死亡率.病情危急,病情危急.在重症监护病房的重症监护病房.这就是MIMIC-IV.肥胖的人肥胖的人三糖-葡萄糖指数是什么意思

更多相关视频

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

相关概念视频

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Obesity

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...